Maintenance PARP inhibition following chemotherapy for metastatic urothelial carcinoma
Maintenance PARP inhibition following chemotherapy for metastatic urothelial carcinoma
First randomized trial on adjuvant mitotane in adrenocortical carcinoma patients: The Adjuvo study.
Durvalumab with olapirib shows no PFS improvement for platinum-ineligible bladder cancer
OncoAlert and ecancer weekly round up for February 7th - 13th, 2022
Update on the new EUSOMA quality indicators for breast cancer
The optimal approach after neoadjuvant treatment: The Lucerne toolbox
Tumour agnostic treatments in GI cancer
Neoadjuvant pembro + chemo vs placebo + chemo, followed by adjuvant pembro vs placebo for early-stage TNBC
Durvalumab plus chemotherapy significantly improved OS in advanced biliary tract cancer
Early treatment discontinuation and early oxaliplatin discontinuation for stage III colorectal cancer
HIMALAYA: Study of tremelimumab and durvalumab as first-line therapy in patients with uHCC
Comparing two chemo regimen and chemoradiotherapy regimen as neoadjuvant treatment for locally advanced oesophageal cancer